Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study(vol 22, 498, 2022)

被引：0
|
作者：
Rayer, Cassandra [1 ]
Nachury, Maria [2 ]
Bourreille, Arnaud [3 ]
Roblin, Xavier [4 ]
Peyrin-Biroulet, Laurent [5 ]
Viennot, Stephanie [6 ]
Flamant, Mathurin [7 ]
Laharie, David [8 ]
Caron, Benedicte [5 ]
Dewitte, Marie [1 ]
Siproudhis, Laurent [9 ]
Fumery, Mathurin [10 ]
Bouguen, Guillaume [9 ,11 ]
机构：
[1] Univ Rennes, CHU Rennes, F-35000 Rennes, France
[2] Univ Lille, CHU Lille, Lille, France
[3] CHU Nantes, Nantes, France
[4] CHU St Etienne, St Etienne, France
[5] Nancy Univ Hosp, Dept Gastroenterol, Inserm U954 Deparment Hepatogastroenterol, Vandoeuvre Les Nancy, France
[6] CHU Caen, Caen, France
[7] Clin Jules Vernes, Nantes, France
[8] Univ Bordeaux, Hop Haut Leveque, Serv Hepatogastroenterol & Oncol Digest, CHU Bordeaux, F-33000 Bordeaux, France
[9] Univ Rennes, Inst NUMECAN Nutrit Metab & Canc, CHU Rennes, INSERM,CIC 1414, F-35000 Rennes, France
[10] Univ Picardie, Serv Hepatogastroenterol & Oncol Digest, CHU Amiens & PeriTox, UMR I0 I, Amiens, France
[11] Serv Malad Appareil Digest, 2 Rue Henri Le Guillou, F-35033 Rennes, France
来源：
BMC GASTROENTEROLOGY | 2023年 / 23卷 / 01期
关键词：
D O I：
10.1186/s12876-022-02636-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies
    Allez, M.
    Vermeire, S.
    Mozziconacci, N.
    Michetti, P.
    Laharie, D.
    Louis, E.
    Bigard, M. -A.
    Hebuterne, X.
    Treton, X.
    Kohn, A.
    Marteau, P.
    Cortot, A.
    Nichita, C.
    van Assche, G.
    Rutgeerts, P.
    Lemann, M.
    Colombel, J. -F.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 31 (01) : 92 - 101
  • [22] Lack of efficacy of first anti-TNF agent is more likely to result in succesful switch to second anti- TNF agent
    Subrahmanyam, Peddasomayajula
    Gendi, Nagui
    Dasgupta, Bhaskar
    RHEUMATOLOGY, 2008, 47 : II30 - II30
  • [23] Durability of a second-line anti-TNFα agent compared to a different mechanism of action after first anti-TNFα failure in ulcerative colitis: CambiaCU Study
    Lopez-Vico, M.
    Hernandez-Martinez, A.
    Soto-Escribano, P.
    Rojas-Feria, M.
    Cornejo-Jimenez, A.
    Caballero-Mateos, A. M.
    Trapero-Martinez, A. M.
    Sanchez-Capilla, A. D.
    Cabello-Tapia, M. J.
    Martin-Rodriguez, M. D. M.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1208 - I1208
  • [24] Comparative Effectiveness of Anti-TNF Therapy and Vedolizumab in Crohn's Disease Patients
    Chen, Nai-Yu
    Chiu, Yung-Ting
    Chuang, Chiao-Hsiung
    Chang, Yu-Ching
    Cheng, Ching-Lan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 356 - 356
  • [25] Effectiveness of a second-line anti-TNFα agent compared to a different mechanism of action after first anti-TNFα failure in ulcerative colitis: CambiaCU Study
    Lopez-Vico, M.
    Hernandez-Martinez, A.
    Soto-Escribano, P.
    Rojas-Feria, M.
    Cornejo-Jimenez, A.
    Caballero-Mateos, A. M.
    Trapero-Martinez, A. M.
    Sanchez-Capilla, A. D.
    Cabello-Tapia, M. J.
    Martin-Rodriguez, M. D. M.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1293 - I1293
  • [26] Is there a benefit from using a subsequent anti-TNF α medication in psoriasis patients who failed their first or second anti-TNF α agent?
    Alsharqi, Ali
    Parslew, Richard
    Dever, Bernadette
    Arslanian, Victoria
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2012, 53 (02) : E45 - E46
  • [27] Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment
    Biemans, Vince B. C.
    van der Woude, C. Janneke
    Dijkstra, Gerard
    van der Meulen-de Jong, Andrea E.
    Lowenberg, Mark
    de Boer, Nanne K.
    Oldenburg, Bas
    Srivastava, Nidhi
    Jansen, Jeroen M.
    Bodelier, Alexander G. L.
    West, Rachel L.
    de Vries, Annemarie C.
    Haans, Jeoffrey J. L.
    de Jong, Dirk
    Hoentjen, Frank
    Pierik, Marieke J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (01) : 123 - 134
  • [28] COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB AND USTEKINUMAB IN ANTI-TNF REFRACTORY CROHN'S DISEASE: MULTI-CENTRE RETROSPECTIVE COHORT STUDY
    Townsend, Tristan
    Razanskaite, Violeta
    Michail, Stephanie
    Morgan, James
    Davies, Michael
    Storey, Daniel
    Watters, Christopher
    Penman, Douglas
    Swaminathan, Mira
    Reilly, Ian
    Flanagan, Paul
    Subramanian, Sreedhar
    GUT, 2021, 70 : A127 - A127
  • [29] The Anti-TNF Agent Infliximab Reverses Inflammatory Sarcopenia in Crohn's Disease
    Subramaniam, Kavitha
    Fallon, Kieran
    Ruut, Thomas
    Mckay, Ross
    Shadbolt, Bruce
    Ang, Sophia
    Cook, Matthew
    Platten, Jan
    Pavli, Paul
    Taupin, Doug
    GASTROENTEROLOGY, 2014, 146 (05) : S597 - S597
  • [30] The anti-TNF agent Infliximab reverses inflammatory sarcopenia in Crohn's disease
    Subramaniam, K.
    Fallon, K.
    Ruut, T.
    Mckay, R.
    Shadbolt, B.
    Platten, J.
    Pavli, P.
    Taupin, D.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 96 - 97
12345